|
Hepatitis B, Chronic
|
0.100 |
Biomarker
|
disease |
BEFREE |
(Pegylated) Interferon ([Peg]IFN) therapy leads to response in a minority of chronic hepatitis B (CHB) patients.
|
30715261 |
2019 |
|
Hepatitis B, Chronic
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Our results can serve as a basis for improving dosing regimens of PEG-IFN alfa-2a in adult patients with chronic hepatitis B or C infection.
|
30179597 |
2018 |
|
Hepatitis B, Chronic
|
0.100 |
Biomarker
|
disease |
BEFREE |
IFN-λ has recently been tested in clinical trials of chronic hepatitis B virus infection (CHB), with the advantage that side effects may be limited compared with IFN-α, as IFN-λ receptors are found only in epithelial cells.
|
30097535 |
2018 |
|
Hepatitis B, Chronic
|
0.100 |
Biomarker
|
disease |
BEFREE |
Baseline intra-patient SHBs diversity was inverse to HBsAg decline in HBeAg-positive chronic hepatitis B (CHB) patients receiving Peg-IFN-α monotherapy.
|
29765238 |
2018 |
|
Hepatitis B, Chronic
|
0.100 |
Biomarker
|
disease |
BEFREE |
The aim of this study was to evaluate the relationship between interleukin-21 (IL-21) and interleukin-21 receptor (IL-21R) polymorphisms and the response to peginterferon alfa (PEG-IFN α) therapy in HBeAg-positive chronic hepatitis B (CHB) patients.A total of 143 HBeAg-positive CHB patients treated for 48 weeks with PEG-IFN α and followed up for 24 weeks post-treatment were retrospectively evaluated.
|
29879024 |
2018 |
|
Hepatitis B, Chronic
|
0.100 |
Biomarker
|
disease |
BEFREE |
However, only a minority of chronic hepatitis B (CHB) patients generate a sustained response after treatment with recombinant IFNα.
|
27839836 |
2017 |
|
Hepatitis B, Chronic
|
0.100 |
Biomarker
|
disease |
BEFREE |
The present study aimed to compare the effect of pegylated interferon (IFN)-α-2a with that of conventional IFN-α-2a on intrahepatic covalently closed circular (ccc)DNA in patients with chronic hepatitis B.
|
26382279 |
2016 |
|
Hepatitis B, Chronic
|
0.100 |
Biomarker
|
disease |
BEFREE |
The aim of this study was to investigate possible involvement of estrogen receptor α (ESR1) in responding to pegylated interferon alpha-2a (PEG IFNα-2a) therapy in chronic hepatitis B (CHB) patients.
|
26485345 |
2016 |
|
Hepatitis B, Chronic
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here, a study was conducted to investigate the dynamic changes in phenotype and function of peripheral γδ T cells in patients with chronic hepatitis B (CHB) during pegylated-interferon (pegIFN)-α treatment, and to explore their roles in IFN-α therapy.
|
25774808 |
2015 |
|
Hepatitis B, Chronic
|
0.100 |
Biomarker
|
disease |
BEFREE |
Association between the IFNA1 (-2Cx2192;T) Polymorphism and Increased IFNAR1 Gene Expression Levels in Chronic Hepatitis B Infection.
|
27101083 |
2015 |
|
Hepatitis B, Chronic
|
0.100 |
Biomarker
|
disease |
BEFREE |
Altered mRNA levels of MOV10, A3G, and IFN-α in patients with chronic hepatitis B.
|
24871977 |
2014 |
|
Hepatitis B, Chronic
|
0.100 |
Biomarker
|
disease |
BEFREE |
Indeed, IFN-α has been successfully used for treatment of patients with chronic hepatitis B.
|
25206268 |
2014 |
|
Hepatitis B, Chronic
|
0.100 |
Biomarker
|
disease |
BEFREE |
Peginterferon α (PEG-IFN), which includes PEG-IFN α-2a (Pegasys) and PEG-IFN α-2b (Peg-Intron), can be used to treat patients with chronic hepatitis B (CHB) infection.
|
24738850 |
2014 |
|
Hepatitis B, Chronic
|
0.100 |
Biomarker
|
disease |
BEFREE |
Prediction of response to interferon α-1b in HBeAg-positive chronic hepatitis B: a clue from HBsAg levels.
|
23411867 |
2013 |
|
Hepatitis B, Chronic
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In this study, the association between the risk of chronic hepatitis B virus infection and the polymorphisms within promoter regions of IFN-α1 and five genes was explored.
|
23566196 |
2013 |
|
Hepatitis B, Chronic
|
0.100 |
Biomarker
|
disease |
BEFREE |
Polymorphisms near IL28B are independently associated with serologic response to PEG-IFN in patients with HBeAg-positive chronic hepatitis B.
|
22108195 |
2012 |
|
Hepatitis B, Chronic
|
0.100 |
Biomarker
|
disease |
BEFREE |
The present study determined type I interferon (IFN) receptor (interferon-α/β receptor (IFNAR)) and its predicable role in interferon-α2b treatment in chronic hepatitis B (CHB) patients.
|
21445562 |
2011 |
|
Hepatitis B, Chronic
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
To investigate whether the JAK-STAT (Janus kinase-signal transducers and activators of transcription) pathway participates in the regulation of APOBEC3G (Apolipoprotein B mRNA-editing enzyme, catalytic polypeptide-like 3G) gene transcription and to study the molecular mechanisms of interferon resistance in patients with chronic hepatitis B (CHB), changes in APOBEC3G and STAT-1 expression levels in HepG2.2.15 cells after treatment with various concentrations of IFN-α, were detected using real-time RT-PCR and Western-blot.
|
20957108 |
2010 |
|
Hepatitis B, Chronic
|
0.100 |
Biomarker
|
disease |
BEFREE |
The practising clinician is currently faced with a number of effective treatment options for chronic hepatitis B, including two formulations of interferon (standard IFN and pegylated IFN) and five nucleos(t)ide analogues (lamivudine, adefovir, entecavir, telbivudine and tenofovir).
|
19187869 |
2008 |
|
Hepatitis B, Chronic
|
0.100 |
Biomarker
|
disease |
BEFREE |
We previously reported that 48 weeks of combination therapy with pegylated interferon-alpha2b (PEG-IFN-alpha2b) and adefovir dipivoxil (ADV) in patients with chronic hepatitis B led to marked decreases of hepatitis B virus (HBV) covalently closed circular DNA (cccDNA) (-2.4 log10 copies/ml).
|
18389899 |
2008 |
|
Hepatitis B, Chronic
|
0.100 |
Biomarker
|
disease |
BEFREE |
Chronic hepatitis B (CHB) patients with advanced fibrosis are often not considered for treatment with peginterferon (PEG-IFN) because IFN therapy may precipitate immunological flares, potentially inducing hepatic decompensation.
|
17604363 |
2007 |
|
Hepatitis B, Chronic
|
0.100 |
Biomarker
|
disease |
BEFREE |
The response to lamivudine therapy shares with IFN a rapid decline in ALT accompanied by an improvement in histology; at variance with IFN, in HBeAg-positive chronic hepatitis B (CHB) there is delayed seroconversion to anti-HBe which accumulates over time, the switch to anti-HBs is more rare and in the long-term, the activity of the drug is abolished by the emergence of viral mutations (YMDD-motif mutants) that may rekindle the disease.
|
14521491 |
2003 |
|
Hepatitis B, Chronic
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In conclusion, our data showed that HBV genotype B was associated with a higher rate of IFN-induced HBeAg clearance compared with genotype C. Stratification for HBV genotypes should be considered in future clinical trials of antiviral therapy of chronic hepatitis B.
|
12447868 |
2002 |
|
Hepatitis B, Chronic
|
0.100 |
Biomarker
|
disease |
BEFREE |
Cloning of woodchuck IFNA genes will allow testing diverse forms of IFN-alpha delivery as well as different combination therapies in woodchuck hepatitis virus infection, thus providing useful information for the design of new strategies for the treatment of patients with chronic hepatitis B.
|
12226832 |
2002 |
|
Hepatitis B, Chronic
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our findings may help to improve the cost-effectiveness of IFN therapy for chronic hepatitis B by guiding the selection of patients for therapy and in optimizing the duration of treatment for the individual patient.
|
9658370 |
1998 |